Log in
Log in
Or log in with
GoogleGoogle
Twitter Twitter
Facebook Facebook
Apple Apple     
Sign up
Or log in with
GoogleGoogle
Twitter Twitter
Facebook Facebook
Apple Apple     
  1. Homepage
  2. Equities
  3. Switzerland
  4. Swiss Exchange
  5. Novartis AG
  6. News
  7. Summary
    NOVN   CH0012005267

NOVARTIS AG

(NOVN)
  Report
Real-time Estimate Cboe Europe  -  03:28 2022-10-04 am EDT
76.92 CHF   +1.23%
10/03Imugene Names Chief Medical Officer; Shares Rise 3%
MT
09/29Moderna Adds New Role Ahead of Product Launches
DJ
09/28Pm(noc) Regulations : Five-year Anniversary Of Major Amendments
AQ
SummaryQuotesChartsNewsRatingsCalendarCompanyFinancialsConsensusRevisionsFunds 
SummaryMost relevantAll NewsAnalyst Reco.Other languagesPress ReleasesOfficial PublicationsSector newsMarketScreener Strategies

U.S. and Switzerland working on facilitating pharma trade - U.S. ambassador

08/13/2022 | 06:31am EDT
FILE PHOTO: Used blister packets that contained medicines, tablets and pills are seen, in this picture illustration

ZURICH (Reuters) - The United States and Switzerland can move towards free trade between their countries with sectoral deals and they are working on facilitating business in the pharmaceutical sector, the U.S. ambassador to Switzerland told the Tages Anzeiger newspaper.

Scott Miller said that in the last round of trade negotiations between the two countries, Switzerland was not prepared to open its agricultural market for U.S. products.

Talks on a free trade agreement between the two countries have stalled.

But Miller said that with the United States now the no. 1 export market for Switzerland, "we can take steps towards free trade by concluding sectoral agreements."

"With regard to the pharmaceutical industry, we are working on facilitating trade," he said in comments published on Saturday.

Switzerland is home to pharma giants Novartis and Roche.

(Writing by Paul Carrel; editing by Clelia Oziel)


© Reuters 2022
Stocks mentioned in the article
ChangeLast1st jan.
NOVARTIS AG 1.08% 76.87 Delayed Quote.-5.36%
ROCHE HOLDING AG 0.67% 324.3 Delayed Quote.-15.04%
All news about NOVARTIS AG
10/03Imugene Names Chief Medical Officer; Shares Rise 3%
MT
09/29Moderna Adds New Role Ahead of Product Launches
DJ
09/28Pm(noc) Regulations : Five-year Anniversary Of Major Amendments
AQ
09/28Europe's generic drugmakers say they may cut output due to energy bills
RE
09/28Europe's generic drugmakers may cut output due to surging energy bills
RE
09/27Monsenso participates in new, large innovation project
AQ
09/27Europe's generic drugmakers may cut output due to surging energy bills
RE
09/27Sandoz Granted Leave To Add New Allegations On Condition Of Trial Adjournment And Exten..
AQ
09/26NOVARTIS AG : UBS reiterates its Neutral rating
MD
09/23NOVARTIS AG : Deutsche Bank gives a Sell rating
MD
More news
Analyst Recommendations on NOVARTIS AG
More recommendations
Financials (USD)
Sales 2022 52 240 M - -
Net income 2022 8 970 M - -
Net Debt 2022 8 348 M - -
P/E ratio 2022 18,7x
Yield 2022 4,30%
Capitalization 167 B 167 B -
EV / Sales 2022 3,36x
EV / Sales 2023 3,31x
Nbr of Employees 108 000
Free-Float 87,1%
Chart NOVARTIS AG
Duration : Period :
Novartis AG Technical Analysis Chart | MarketScreener
Full-screen chart
Technical analysis trends NOVARTIS AG
Short TermMid-TermLong Term
TrendsBearishBearishNeutral
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus HOLD
Number of Analysts 25
Last Close Price 76,61 $
Average target price 90,00 $
Spread / Average Target 17,5%
EPS Revisions
Managers and Directors
Vasant Narasimhan Chief Executive Officer
Harry Werner Kirsch Chief Financial Officer
Hans Jörg Reinhardt Non-Executive Chairman
Shreeram Aradhye Chief Medical Officer
Steffen Lang President-Operations
Sector and Competitors
1st jan.Capi. (M$)
NOVARTIS AG-5.36%167 230
JOHNSON & JOHNSON-4.60%429 503
ELI LILLY AND COMPANY17.06%307 239
ROCHE HOLDING AG-14.68%271 055
PFIZER, INC.-25.25%245 597
ABBVIE INC.-0.88%237 296